{"entity":{"id":"nct05944978","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","aka":[],"tldr":"A phase 1/2 trial of GNC-035 in chronic lymphocytic leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies is a phase 1/2 interventional study registered as NCT05944978 by Sichuan Baili Pharmaceutical Co., Ltd., with 3 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-035.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05944978","url":"https://clinicaltrials.gov/study/NCT05944978"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05944978","phase":"1/2","setting":"Phase Ib/II Clinical Study of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":3,"outcomes":[]},"route":"/trials/nct05944978/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}